小柯机器人

丹麦哥本哈根大学Oluf Pedersen、英国伦敦大学S. Dusko Ehrlich、英国伦敦帝国理工学院Marc-Emmanuel Dumas以及法国索邦大学Karine Clément团队合作取得一项新成果。他们揭示心脏代谢疾病谱的微生物组和代谢组特征。这一研究成果于2022年2月17日发表在国际顶尖学术期刊《自然—医学》上。

在缺血性心脏病 (IHD) 的背景下，他们使用了一种研究设计，该设计概括了疾病的起始、升级和对治疗的反应，反映了一项纵向研究，或鉴于 IHD 发病机制的长期性质，该研究很难进行。他们招募了 1,241 名欧洲中年人，包括健康个体、代谢异常疾病（肥胖和 2 型糖尿病）但缺乏明显 IHD 诊断的个体以及处于三个不同临床阶段（急性冠状动脉综合征、慢性 IHD 和 IHD 伴心力衰竭）的 IHD 个体。并对它们的表型组、肠道宏基因组以及血清和尿液代谢组进行了表征。他们发现，在调整药物和生活方式的影响后，将 IHD 个体与健康个体区分开来的约 75% 的微生物组和代谢组特征存在于表现出代谢障碍的个体中，这表明肠道微生物组和代谢组的重大改变可能在临床发作之前很久就开始了的 IHD。

他们进一步对与前驱代谢障碍相关的微生物组和代谢组特征进行分类，这些特征通常特定于 IHD 或其三种亚型中的每一种或与 IHD 的升级或降级有关。与传统的风险标志物相比，基于特定 IHD 微生物组和代谢组特征的判别分析可以更好地将 IHD 个体与健康个体或代谢匹配个体区分开来，指出这些特征的病理生理学相关性。

据了解，以前探索非传染性疾病的微生物组和代谢组分析很少关注研究结果的主要混杂因素，例如常见、病前和合并症，或多种药物。

附：英文原文

Title: Microbiome and metabolome features of the cardiometabolic disease spectrum

Author: Fromentin, Sebastien, Forslund, Sofia K., Chechi, Kanta, Aron-Wisnewsky, Judith, Chakaroun, Rima, Nielsen, Trine, Tremaroli, Valentina, Ji, Boyang, Prifti, Edi, Myridakis, Antonis, Chilloux, Julien, Andrikopoulos, Petros, Fan, Yong, Olanipekun, Michael T., Alves, Renato, Adiouch, Solia, Bar, Noam, Talmor-Barkan, Yeela, Belda, Eugeni, Caesar, Robert, Coelho, Luis Pedro, Falony, Gwen, Fellahi, Soraya, Galan, Pilar, Galleron, Nathalie, Helft, Gerard, Hoyles, Lesley, Isnard, Richard, Le Chatelier, Emmanuelle, Julienne, Hanna, Olsson, Lisa, Pedersen, Helle Krogh, Pons, Nicolas, Quinquis, Benoit, Rouault, Christine, Roume, Hugo, Salem, Joe-Elie, Schmidt, Thomas S. B., Vieira-Silva, Sara, Li, Peishun, Zimmermann-Kogadeeva, Maria, Lewinter, Christian, Sndertoft, Nadja B., Hansen, Tue H., Gauguier, Dominique, Gtze, Jens Peter, Kber, Lars, Kornowski, Ran, Vestergaard, Henrik, Hansen, Torben, Zucker, Jean-Daniel, Hercberg, Serge, Letunic, Ivica, Bckhed, Fredrik, Oppert, Jean-Michel, Nielsen, Jens, Raes, Jeroen, Bork, Peer, Stumvoll, Michael, Segal, Eran, Clment, Karine, Dumas, Marc-Emmanuel

Issue&Volume: 2022-02-17

Abstract: Previous microbiome and metabolome analyses exploring non-communicable diseases have paid scant attention to major confounders of study outcomes, such as common, pre-morbid and co-morbid conditions, or polypharmacy. Here, in the context of ischemic heart disease (IHD), we used a study design that recapitulates disease initiation, escalation and response to treatment over time, mirroring a longitudinal study that would otherwise be difficult to perform given the protracted nature of IHD pathogenesis. We recruited 1,241 middle-aged Europeans, including healthy individuals, individuals with dysmetabolic morbidities (obesity and type 2 diabetes) but lacking overt IHD diagnosis and individuals with IHD at three distinct clinical stages—acute coronary syndrome, chronic IHD and IHD with heart failure—and characterized their phenome, gut metagenome and serum and urine metabolome. We found that about 75% of microbiome and metabolome features that distinguish individuals with IHD from healthy individuals after adjustment for effects of medication and lifestyle are present in individuals exhibiting dysmetabolism, suggesting that major alterations of the gut microbiome and metabolome might begin long before clinical onset of IHD. We further categorized microbiome and metabolome signatures related to prodromal dysmetabolism, specific to IHD in general or to each of its three subtypes or related to escalation or de-escalation of IHD. Discriminant analysis based on specific IHD microbiome and metabolome features could better differentiate individuals with IHD from healthy individuals or metabolically matched individuals as compared to the conventional risk markers, pointing to a pathophysiological relevance of these features.

DOI: 10.1038/s41591-022-01688-4

Source: https://www.nature.com/articles/s41591-022-01688-4

Nature Medicine：《自然—医学》，创刊于1995年。隶属于施普林格·自然出版集团，最新IF：87.241
官方网址：https://www.nature.com/nm/
投稿链接：https://mts-nmed.nature.com/cgi-bin/main.plex